The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
A wide inter-individual variation in response to lipid lowering therapy has been observed, although a good efficacy of such therapy has been documented. The aim of the present study was to investigate the possible role of apolipoprotein B (apo B) XbaI genotype on this variation. The apo B XbaI genotype was determined in 89 patients with non-familial type II hypercholesterolemia. Simvastatin (5...
An increase susceptibility of lipid to peroxidation in type II hypercholesterolemia has been described. This study was designed to evaluate whether lipid peroxidation could be reduced in patients with type II hypercholesterolemia after lipid lowering therapy. Simvastatin 5 mg/day and theofibrate 500 mg/day were administered to 62 and 27 type II hypercholesterolemic patients respectively for 12 weeks...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.